Now, there could be another alternative, in the form of eye drops administered daily, according to AbbVie's Allergan subsidiary, which reported new phase 3 data for its pilocarpine formulation ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback